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Metastasis is the major cause of death in colorectal cancer patients, mainly due to the 
ineffectiveness of current therapies once metastases begin to form. Further insight into 
the biology of colorectal cancer metastasis is therefore essential in order to gain a greater 
understanding of this process and ultimately to develop better cancer therapies to prevent 
or target metastasis. LGR5 is leucine-rich repeat containing G protein-coupled receptor 
(GPCR) and was discovered as a marker for proliferating adult stem cells in small 
intestine. LGR5 and its homologs LGR4 and LGR6 are receptors of R-spondins (RSPOs), 
which are secreted agonists of canonical Wnt signaling. Upon binding RSPOs, they form 
a physical complex with Wnt receptor Frizzled and its co-receptor LRP6 to regulate Wnt 
canonical signaling. Here we show that RSPO-LGR5 activates TGFβ signaling in colon 
cancer cells, enhancing TGFβ-mediated growth inhibition and stress-induced apoptosis. 
Knockdown of LGR5 attenuates TGFβ signaling, increases cell proliferation, survival 
and metastasis. Mechanistically, with the presence of RSPOs, LGR5 forms and enhances 
complex formation with TGFβ receptors to activate downstream signaling. Our study 
underlies a novel crosstalk between Wnt and TGFβ signaling in colon cancer cells. Since 
TGFβ signaling is defective in most late stage colon cancer and its restoration has been 
shown to suppress colon cancer tumorigenicity, our findings would provide an alternative 
mechanism to activate TGFβ signaling and suppresses colon cancer tumorigenicity and 
metastasis.   
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1.1 Overview of Colorectal Cancer Disease 
1.1.1 Colorectal Cancer Facts and Statistics 
New Cases and Death Rate: Colorectal (colon and rectum) cancer is expected to be the 
third leading cause of cancer related death in both men and women based on 2007-2011 
cases and deaths record from the USA National Cancer Institute.  In the year 2014, it is 
estimated that there will be 136,830 new cases of colorectal cancer and an estimated 
50,310 people will die of this disease (Figure1.1).  
Risks Factors: Hereditary and medical factors that increase risk to colorectal cancer 
include a personal or family history of colorectal cancer or polyps, a personal history of 
chronic inflammatory bowel disease (e.g., ulcerative colitis or Crohn disease), certain 
inherited genetic conditions (e.g., Lynch syndrome) and type 2 diabetes.  
Stage of Colorectal Cancer: As many other cancer types, colorectal cancer disease is 
treated and managed according to their stages. Currently, the most commonly used 
staging system is the TNM (Tumor, Node, Metastasis) staging system (Figure 1.2), 
which reflects the depth and the potential spread of the tumor. The anatomic TNM 
staging system of colon cancer has greatly benefited the management of the disease, 
however, oncologists are still facing the challenge of cancer recurrence risks and patients 
response to intervention therapies. At this time, efforts are being made to identify the 
genes and proteins that are associated with cancer initiation and/or recurrence. One 
advancement is the development of multi-gene assays that provide prognostic and 
predictive information to aid in decisions regarding adjuvant therapy in patients with 
colon cancer (Benson and Hamilton 2011). 
!
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Survival Rate: Localized cancer is referred to as stage I cancer. If it has spread to a 
different part of the body, the stage is regional or distant. The earlier colon and rectum 
cancer is caught, the better chance a person has of surviving five years after being 
diagnosed. The overall 5-year survival rate for colorectal cancer is 64.7%. However, 
cancer stage has a strong influence on the length of survival. At the time of diagnosis, 
there are about 40% of patients presenting with localized tumors, 36% of patients have 
the disease spread to regional lymph nodes and 20% of them have distal metastasis. The 
5-year survival rate for patients with localized and regional tumor is 89.8% and 70.5%, 
respectively. While it drops dramatically to 12.9% when the tumor has metastasized to 
other organs (Figure 1.3).  
Early Detection and Treatment: At the age of 50, men and women who are at average 
risk are encouraged to begin screening for colorectal cancer. Screening can detect cancer 
at an early stage and also allow for the removal of colorectal polyps that might become 
cancerous. Surgery is the most common treatment for all stages of cancer. Even if the 
surgery removes all the cancer that can be seen at the time of the operation, some patients 
may be given chemotherapy or radiation therapy after surgery (i.e., adjuvant therapy) to 
kill any cancer cells that are remaining in the body. Presently, researchers have 
discovered more about the gene and protein profiles in cells that cause cancer and newer 
drugs that specifically target the cancer cells are being developed (i.e., targeted therapy). 
For example, some monoclonal antibodies and inhibitors have been used in combination 
with the other treatments to attack the epidermal growth factor receptor (EGFR), vascular 
endothelial growth factor (VEGF) and some kinases that prompt cancer cells to grow. 
However, as the outcome of patients with metastasis or with later stage of tumor is still 
!
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poor, more efforts are being made to elucidate better prognostic biomarkers and 
prediction biomarkers to improve the management and to assess total outcome after 
certain treatments in colorectal cancer patients.  
1.1.2 Colon Cancer Progression 
Cancer progression involves all of the changes that transform cells from normal to 
cancerous. The transformation of colon epithelium cells from normal to life-threatening 
metastatic cancer cells can be dissected into the following key steps: adenoma initiation, 
carcinoma initiation and metastatic cell initiation. In this section, I will introduce the 
progression process of colorectal cancer on both the morphological level and the 
molecular level. 
1.1.2a Morphological Progression:  Most colorectal cancers progress through a series of 
morphological changes (Figure 1.4). In the first histological signs, one or more crypts 
will show accumulation of excess cells at the epithelial surface. The cells in these 
aberrant crypt foci may appear normal (i.e., hyperplasia), or show some abnormality (i.e., 
dysplasia). The accumulated cells will grow out from the epithelial surface to form a 
polyp or an early adenoma, but all cells are growing within the epithelial mucosa at this 
stage. However, as an early adenoma continues to grow, it will obtain more intracellular 
disorders to become a later adenoma or an invasive carcinoma. At these stages, cells will 
display more histological abnormality; tumors are tending to invade and infiltrate local 
structures and, eventually, spread from the site of its origin to adjacent and/or distant sites 
in the body, i.e., metastasis.  
Metastasis is widely accepted as a multi-step process that involves the following steps 
!
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(Figure 1.5):  
Local Invasion and Intravasation: Cancer cells invade into the local normal tissue 
and/or migrate into the nearby lymph vessels or blood vessels. 
Survive in Circulation System: Cancer cells start to circulate in the lymphatic and/or the 
blood circulation system. They need to survive against the harsh conditions and escape 
from the surveillance of the immune system to reach other parts of the body. 
Arrest and Extravasation: Cancer cells arrest in capillaries at a distant location. They 
then invade the walls of the capillary vessels and migrate into the surrounding tissue. 
Tumorigenicity and Proliferation: Cancer cells start amplification at the secondary site 
to form micrometastases. 
Angiogenesis: Micrometastases stimulate the growth of new blood vessels to obtain the 
oxygen and nutrients necessary for continued tumor growth to form macrometastases.  
However, only a very small population of cancer cells is capable of going through all the 
processes and form metastasis at the secondary site, counting on the malignant properties 
of individual cells. Thus, to study metastasis, the aforementioned properties and 
phenotype changes are widely used in research field as critical indicators to determine a 
metastatic cell. 
1.1.2b Molecular Progression: It is widely accepted that particular molecular changes 
often associate with morphological stage and play important roles in driving progression. 
Studies from the past few decades have revealed that the following three genetic and/or 




The Chromosomal Instability (CIN): A type of chromosomal abnormality, such that 
either whole or part of the chromosome are deleted or duplicated, leading to the DNA 
copy number variation (CNV), which results in a series of genetic changes that involve 
the activation of oncogenes such as KRAS and inactivation of tumor suppressor gene such 
as TP53, DCC/SMAD4, and APC. Synergistically, these gene alterations will also 
accelerate the alteration rate of the genome stability. CIN accounts for around 85% of 
colorectal cancer cases.  
Inherited Mismatch Repair (MMR) Deficiency: Inherited mutations in the DNA MMR 
system cause microsatellite instability (MSI), which causes alterations of genes such as 
transforming growth factor receptor II (TGFBR2) and BAX.  
Epigenetic hypermethylation: Silencing of MMR or other DNA repair system by 
hypermethylation on their corresponding functional gene’s promoter also results in an 
increased MSI and somatic mutation rate.  
The aforementioned events will directly result in a substantial amount of genetic/genomic 
changes (i.e., DNA copy number variation, somatic mutation and mRNA expression 
changes) during the process of cancer progression. However, only few of altered genes 
are playing the ‘drivers’ role, companied with enormous passenger genes’ alterations. A 
rich history of investigations has uncovered several critical genes and pathways important 
in the initiation and progression of colorectal cancer, which has been summarized in 
Figure 1.4. Briefly, the initiation of adenoma is mostly driven by the mutation of APC 
and/or CTNNB1, the two regulatory gene of the canonical Wnt signaling pathway. 
Mutation of RAS is contributed to the transformation of an early adenoma to an 
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intermediate adenoma. Mutation of DCC, SMAD2 and SMAD4 result in a deregulation of 
Wnt and TGFβ signaling pathways and drive the tumor to grow into late stage adenoma. 
The initiation of carcinoma usually occurs in accompany with the homozygous mutation 
of TP53 and TGFBR2 mutation. These genes function as tumor suppressors that inhibit 
cell division and introduce cell apoptosis under stress. Tumor cells, which escape from 
the surveillance of these proteins, will consequently transform into cancerous stages.  
In terms of metastasis, the following three theories have been widely accepted to explain 
the origin and rising of metastatic cells.  
Cancer Stem Cell Theory: Recently, several concepts regarding the origins of cancer and 
metastasis have converged. Special interest has focused on the possibility that normal 
tissue specific stem cells and cancer stem cells also known as cancer initiating cells play 
fundamental roles in the malignant process. The cancer stem cell theory proposed that 
cancer stem cells, mostly rising from normal somatic stem cells, are origin of cancer 
(Barker, Ridgway et al. 2009). These cells may be numerically rare in primary tumor but 
nonetheless give rise to the distal metastasis and account for the poor response to 
intervention therapies in cancer patients (Dean 2005, Huang and Wicha 2008). Several in 
vitro and in vivo studies have proved such cells are present in colorectal cancer and other 
solid tumors. The normal stem cell surface markers, CD133, CD44 and EpCAM, as well 
as other stem cell-associated proteins, nestin, Bmi1 and Msi-1 can be used to identify the 
colon cancer stem cell population. (Ricci-Vitiani, Fabrizi et al. 2009).  
Multi-Progression Theory: Alternatively, the multi-progression theory proposed that 
metastatic cells could arise at different stages from different origin of cells. Broadly, 
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further accumulations of the genetic changes in cancer cells are required to drive the 
progression to metastatic stages. However, the genetic mutation rate and progression 
speed present an enormous variation among patients (Campbell, Yachida et al. 2010). 
This theory emphasizes that the ongoing clonal transformation/‘evolutions’ among cells 
in both the primary tumor and secondary lesion are the causative reason of metastases, 
but the accomplishment of the transformation/‘evolution’ happens in a stochastic manner 
depending on when the cancer cells could acquire the mutations on the metastatic drivers 
gene. Comparative analysis between metastatic and non-metastatic cells revealed that 
differential expression of certain genes is associated with the metastatic potential of 
cancer cells (Hernandez, Smith et al. 2000, Ji, Greening et al. 2013). Don X. Nguyen et. 
al., reviewed several studies in characterizing some molecules that drive the progression 
on each step of metastasis (Figure 1.6) (Nguyen, Bos et al. 2009). Previous studies from 
Dr. Brattain’s and Dr. Wang’s lab also showed that PIK3CA mutations (Guo, Rajput et al. 
2007), genes altered in TGFβ signaling pathway (Wang, Han et al. 1996, Wang, Yang et 
al. 2008, Liu, Rajput et al. 2011) and loss of microRNA-192 expression (Geng, 
Chaudhuri et al. 2014) play critical roles in colon cancer metastasis.  
Cancer-Stromal Crosstalk Theory: Efforts also have been made in studying the cancer-
stromal crosstalk and genetic changes in stromal tissue in cancer progression for the past 
two decades. Multiple reports have demonstrated that cancer cells can produce a range of 
growth factors (e.g. bFGF, VEGF, PDGF, and TGFβ) that modulate their surrounding 
stromal cells to activate critical signals that drive proliferation, angiogenesis, and motility 
while suppressing cell death (Mueller and Fusenig 2004). Increasing evidence has also 
indicated that the stromal cells themselves may also obtain mutations from environmental 
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stimulation or inherited genetic or genomic events to promote cancer to metastasize 
(Tlsty and Hein 2001).  
As a summary of this section, the morphological change of colorectal cancer progression 
is always accompanied with certain amount of molecular deregulations, which may be 
playing the driver’s role in promoting the progression process. Several theories have been 
applied to identify the malignant cells that carry the most altered and critical molecular 
changes during the disease progression. Therefore, a comprehensive understanding of 
colorectal cancer progression models on both morphological and molecular levels is very 
important for studying colon cancer, which ultimately will shed lights on the 





Figure 1.1 New Cases and Deaths of CRC. The number of new cases of colon and 
rectum cancer was 43.7 per 100,000 men and women per year, accounting for 8.2% of all 
new cancer cases. The number of deaths was 15.9 per 100,000 men and women per year, 
counting for 8.6% of all cancer deaths. Approximately 4.7 percent of men and women 
will be diagnosed with colon and rectum cancer at some point during their lifetime, based 
on 2009-2011 data. And the five-year survival rate is about 64.7%, based on 2004-2010 
data.  














































































































































































Figure 1.3 Percent of Cases and 5-Year Relative Survival by Stage at Diagnosis. At 
the time of diagnosis, there are about 40% of patients presenting with localized tumors, 
36% of patients have the disease spread to regional lymph nodes and 20% of them have 
distal metastasis. The 5-year survival rate for patients with localized and regional tumor 
is 89.8% and 70.5%, respectively. While it drops dramatically to 12.9% when the tumor 
has metastasized to other organs. 





Figure 1.4 Classic Molecular Progression of Colon Cancer. Particular genetic changes 
often associated with the morphological stage, suggesting that the genetic changes play 
an important role in driving progression. Approximately 50–85% of colorectal cancers 
follow this pathway. (Frank 2007) (Fleming, Ravula et al. 2012) 
Figure is rewrote from Figure 3.2 of Frank 2007, H&E stainings were obtained from 




Figure 1.5 Multi-step Processes of Cancer Metastasis. The process begins with a. an in 
situ cancer.! b. Invasion requires destruction of proteins in the matrix and stroma, EMT 
changes and increased motility of cancer cells. c. Metastatic cells can enter via the 
lymphatics, or d. directly through the circulation. e. Metastatic cells survive and arrest in 
the secondary site, and extravasation of the circulatory system follows. f. Metastatic 
colonization of the secondary site progresses through single cells to micrometastases and 
g. progressively grows into macrometastases. (Steeg 2003) 
Figure was obtained from Figure 1 of Steeg 2003 with permission. 
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R E V I EW S
carrying a single human tagged chromosome are used
to transfer the chromosome into recipient metastatic
cells, and the in vivo metastatic behaviour is then deter-
mined. If found to suppress metastasis, the region of
the chromosome is successively narrowed to candidate
genes, which are studied for expression patterns and
function in transfection experiments.
Validation of metastasis-suppressor function
depends on experiments in which the proposed sup-
pressor is transfected into a metastatically competent
cell line expressing reduced levels of the putative sup-
pressor. Its re-expression at physiological levels in
clonal transfectants should have no impact on pri-
mary tumour size in spontaneous metastasis assays,
compared with vector alone transfectants, but should
significantly reduce metastasis formation. Many of
the metastasis-suppressor genes identified have been
confirmed in several cell types to show the generality
of their function. However, NM23 and KAI1 have not
always been shown to suppress metastasis8,9, which
indicates the context dependence of suppressive path-
ways. In addition, cohort studies have correlated the
reduced expression of a metastasis suppressor to indi-
cators of clinical aggressiveness, such as patient sur-
vival, development of nodal or distant metastases, and
tumour stage or grade (for example, see REFS 10,11).
These studies are not aimed at a statistical level of
prognostic ability, but do provide evidence that data
accumulated in model systems are relevant to the
progression of human tumours.
Metastasis suppressors seem to operate at many
phases of the metastatic process, including the clinically
applicable final step of metastatic colonization (FIG. 1).
Many of the known metastasis suppressors would not
have been predicted a priori as they do not have a
known biochemical function that is consistent with
what is known about invasion and metastasis.
Biochemical investigation of metastasis suppressors has
led to the identification of new pathways and functions
that are crucial to the metastatic process.
So how do metastasis suppressors impact on both
familiar and novel signal-transduction pathways?
Also, do metastasis suppressors identify new anti-
metastatic therapeutic targets and do they alter our
consideration of therapeutic strategies that target
‘established’ signal-transduction pathways?
NM23. NM23 was identified simultaneously by its
reduced expression in highly metastatic melanoma
cell lines (as compared with related, tumorigenic, but
poorly metastatic lines)12 and by the requirement for
the NM23 Drosophila homologue for the differentia-
tion of presumptive adult epithelial tissues in the
imaginal discs of Drosophila13,14. Transfection of
NM23 into ten metastatically competent cell lines
reduced in vivo metastatic potential (TABLE 1). In addi-
tion to its in vivo metastasis-inhibitory activity,
transfection of human NM23 into human breast car-
cinoma cells reduced in vitro motility to numerous
attractan s15, inhibited colonization in soft agar —
both alone and in response to transforming growth
metastasis suppressors. Another method for metastasis-
suppressor identification uses microcell-mediated
chromosome transfer (reviewed in REF. 7) to identify a
chromosomal region that has suppressive activity 
in vivo. In this approach, well-characterized donor cells
Summary 
• Metastasis-suppressor genes are identified by their reduced expression in highly
metastatic, compared with tumorigenic but poorly or non-metastatic, tumour cells.
Following re-expression of a metastasis-suppressor gene in a tumour cell line, in vivo
metastasis is inhibited, without a significant reduction in tumorigenicity.
• Eight metastasis-suppressor genes have been confirmed so far. They affect many
aspects of signal transduction, including pathways that are involved in invasion,
growth-factor-receptor signalling, the mitogen-activated protein kinase pathway,
cell–cell communication and transcription.
• Many metastasis suppressors affect metastatic colonization — the final outgrowth of
tumour cells after they have arrived at a distant site — by non-angiogenic means.
Re-expression of metastasis-suppressor expression in micrometastatic tumour cells
might halt their further progression with a clinical benefit.
• The loss of metastasis-suppressor expression in metastatic lesions indicates that several
aspects of signal transduction are compromised, compared with non-metastatic
tumour cells.Preclinical drug testing based on primary tumour size in mice might not
reflect these important differences, and metastatically competent model systems might
predict clinical efficacy more accurately.
a  In situ cancer b  Invasion of the tumour border 
c  Lymphatic spreadd  Intravasion of the circulatory system
     Survival, transport  
e  Arrest 
     Extravasion
f  Solitary dormant cells
    Occult micrometastases
g  Progressive colonization
     Angiogenesis
Figure 1 | Metastasis is a complex, multistep process. A schematic of the metastatic
process, beginning with a | an in situ cancer surrounded by an intact basement membrane. 
b | Invasion requires reversible changes in cell–cell and cell–extracellular-matrix adherence,
destruction of proteins in th  matrix and stroma, and motility. Metastasizing cell  can c | enter via
the lymphatics, or d |directly enter the circulation. e | Survival and arrest of tumour cells, and
extravasation of the circulatory system follows. f | Metastatic colonization of the distant site
progresses through single cells, which might remain dormant for years, to occult




Figure 1.6 Metastasis-associated Genes. Functionally classified genes are associated 
with different steps of colon cancer development (Nguyen, Bos et al. 2009)  
Figure was obtained from Figure 1 of Nguyen, Bos et al. 2009 with permission. 
Metastasis virulence functions: organ-specific colonization 
PTHRP, IL11, CSF2RB (GM-CSF), IL6, TNF
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Metastasis initiation functions: invasion, angiogenesis, marrow mobilization and circulation 
Gain of TWIST1, SNAI1, SNAI2, MET, ID1, 
Loss of KISS1, miR-126, miR-335, DARC, GPR56
Tumour initiation functions: growth, survival, progenitor-like state and genomic instability 
Oncogenes: ERBB2, CTNNB1 ( -catenin), KRAS, PI3K, EGFR, MYC








Metastasis progression functions: extravasation, survival and reinitiation 
PTGS2, EREG, MMP1, LOX, ANGPTL4, CCL5 targets
in the context of genomic instability,  and subsequently 
their expression could become stabilized as it provides 
a selective advantage to malignant cells in a particular 
microenvironment. These genes would not contribute to 
the expression signatures that are predictive of metastasis 
in primary tumours.
The temporal course of metastasis
The diverse temporal courses of metastasis in different 
types of cancer and patient populations are evident from 
clinical observations. As the kinetics of disease progres-
sion and distinct physiological barriers can dictate the 
latency between the infiltrating and colonizing steps of 
metastasis, each clinical course has different implica-
tions for the organ-selective evolution of metastatic cell 
populations (FIG. 4). In oestrogen receptor-positive  breast 
cancer, prostate cancer and ocular melanoma, metasta-
sis might become manifest decades after the removal of 
even a small primary malignancy11,32,33. The absence 
of immediate clinical relapse implies that these tumour 
cells are not fully competent to overtake organs imme-
diately after infiltration. A protracted period of latency 
might ensue during which further malignant evolution of 
the disseminated cell population, of their microenviron-
ment or of both must occur for colonization to proceed.
In other types of cancer, however, metastasis follows a 
swift course with rapid expansion in multiple organs that 
leaves little margin for speciation of the metastatic cell 
population. For example, in lung cancers and pancreatic 
adenocarcinomas, malignant cells might rapidly acquire 
activities that confer both infiltration and colonization 
competence, as implied by the short time between pri-
mary tumour diagnosis and metastatic relapse in these 
diseases16,34. In tumours with a rapid course of metastasis, 
the acquisition of robust metastatic traits in the primary 
tumour would obviate the need for extensive adaptation 
on dissemination to distant organs.
Colorectal carcinoma is a defined paradigm of malignant 
progression and most metastatic traits seem to be acquired 
during local progression in the primary site. The transition 
from one stage to the next — from colorectal hyperpla-
sia to adenoma to invasive carcinoma — is characterized 
by the acquisition of specific genetic alterations over a 
protracted period of up to three decades35. Colorectal 
tumours are initiated by the activation of the canonical 
Wnt pathway, through either mutational inactivation of 
the tumour suppressor adenomatous polyposis coli (APC) 
or activation of the pathway co-activator β-catenin36. The 
transition to carcinoma occurs with mutational activation 
of KRAS37, followed by oncogenic activation of the PI3K 
pathway38, inactivation of TP53 (REF. 39) and loss of the 
transforming growth factor-β (ΤGFβ) tumour suppressor 
pathway40. Once a colon tumour invades the underlying 
colonic wall, metastatic progression can proceed without 
latency. Colorectal tumours predominantly spread along 
the mesenteric circulation to the liver in 80% of patients 
Figure 1 | Basic steps of metastasis and hypothetical classes of metastasis genes. The basic steps of metastasis 
include the progression of the primary tumour towards invasive carcinoma and dispersion of cancer cells through the 
lymphatic or blood vessels. Circulating ancer cells that survive could infiltrate dist nt organs. Infiltrated c lls in the new 
microenvironment might proceed towards overt metastasis with or without an intervening period of latency. These steps 
are supported by functions of the cancer cells themselves or of the tumour stroma. In addition to the tumour-initiating 
events that produce an incipient carci oma (only some examples are listed), metastasis requires functionally distinct 
classes of genes that provide metastasis initiation, progression and virulence functions. These functions can be acquired 
through distinct genetic or epigenetic alterations, and might collectively endow circulating cancer cells with the 
competence to infiltrate, survive in latency and colonize distant organs. ANGPTL4, angiopoietin-like 4; APC, adenomatous 
polyposis coli; CCL5, C-C chemokine ligand 5; DARC, Duffy antigen chemokine receptor; EGFR, epidermal gr wth factor 
receptor; EREG, epiregulin; GM-CSF, granulocyte–macrophage colony stimulating factor; GPR56, G protein-coupled 
receptor 56; HGF, hepatocyte growth factor; ID1, inhibitor of differentiation 1; IL, interleukin; KISS1, kisspeptin 1; LOX, 
lysyl oxidase; MMP1, matrix metalloproteinase 1; PTGS2, prostaglandin G/H synthase 2; PTHRP, parathyroid 
hormone-related protein; TNFα, tumour necrosis factor-α.
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1.2  Altered Signaling Pathways in CRC 
Combined with the classic genetic alteration models that are described in the last section, 
a comprehensive molecular study in colorectal cancer from The Cancer Genome Atlas 
(TCGA) Network in 2012 has also enriched people’s understanding of how some well-
defined pathways are deregulated (Cancer Genome Atlas 2012). The group has conducted 
an integrated analysis of mutations, DNA copy number alterations, promoter methylation 
status and messenger RNA and microRNA expression. From their analysis, they found 
that the Wnt signaling pathway was altered in 93% of all tumors, including biallelic 
inactivation of APC or activating mutations of CTNNB1 in 80% of cases, which indicates 
that Wnt signaling alterations are prerequisites of tumor initiation. The TCGA group also 
found the TGFβ signaling pathway is universally deregulated with genomic alterations in 
TGFBR1, TGFBR2, ACVR2A, ACVR1B, SMAD2, SMAD3 and SMAD4 in 27% of the 
non-hypermutated and 87% of the hypermutated tumors. Genetic alterations in the PI3K 
and RAS-MAPK pathways are also common in CRC. The p53 pathway was found 
altered in 59% of non-hypermutated cases. 
Therefore, according to this TCGA’s analysis, together with a history of studies in CRC, 
activation of the Wnt signaling pathway at the onset of tumorgenisis and inactivation of 
the TGFβ signaling pathway in later progression stages are nearly ubiquitous events in 
CRC. In this dissertation, I will demonstrate the novel crosstalk between TGFβ signaling 
pathway and a Wnt target gene, LGR5.  
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1.2.1 Canonical Wnt Signaling Pathway 
The canonical Wnt signaling pathway has been well characterized from two decades of 
studies. As was illustrated in Figure 1.7, in the absence of Wnt ligands, β-catenin is 
constantly degraded by the destruction complex, which is composed of the scaffolding 
protein Axin, the tumor suppressor adenomatous polyposis coli gene product (APC), 
casein kinase 1 (CK1), and glycogen synthase kinase 3 (GSK3). CK1 and GSK3 
sequentially phosphorylate the N-terminal region of β-catenin, resulting in the 
recruitment of β-Trcp, an E3 ubiquitin ligase subunit, and subsequent β-catenin 
ubiquitination and proteasomal degradation. This continual distruction of β-catenin 
prevents the accumulation of this protein and translocation to nucleus. In this case, Wnt 
target genes are repressed by TCF-TLE/Groucho and histone deacetylases (HDAC). With 
the presence of Wnt ligands, the seven-transmembrane receptor Frizzled (Fz) and its co-
receptor, low-density lipoprotein receptor related protein 6 (LRP6) or its close relative 
LRP5 will activate and form a likely Wnt-Fz-LRP6 complex. The complex formation 
will recruit the scaffolding protein Dishevelled (Dvl) to phosphorylate LRP6 and 
sequentially activate the destruction complex. These events lead to inhibition of Axin-
mediated β-catenin phosphorylation and thereby to the stabilization of β-catenin. 
Accumulated cytoplasmic β-catenin will travel to the nucleus to replace the repressors 
from TCF/LEF and activate Wnt target gene expression (MacDonald, Tamai et al. 2009).  
1.2.2 Roles of LGR5 and RSPOs in Colorectal Cancer 
LGR5 (GPR49) is a leucine-rich repeat containing G protein-coupled receptor (GPCR) 
and one of the LGR family members (Hsu, Liang et al. 1998, McDonald, Wang et al. 
1998). As most of the other GPCRs, the structure of LGR5 and its homologues, LGR4 
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and LGR6, contain an N-terminal extracellular domain (i.e., ectodomain), a seven-
transmembrane domain and a C-terminal intracellular domain (Figure 1.8).  
LGR5 and its homologs LGR4 and LGR6 are receptors of R-spondins (RSPOs) (Carmon, 
Gong et al. 2011, de Lau, Barker et al. 2011, Glinka, Dolde et al. 2011), which are 
secreted agonists of canonical Wnt signaling (Binnerts, Kim et al. 2007, Kim, Wagle et 
al. 2008). Peng and de Lau et al., first reported the crystal structure of a Fu1-Fu2 
fragment of RSPO1 and its complex with the ligand-binding ectodomain of LGR5 (Peng, 
de Lau et al. 2013). And this short RSPO1 Fu1-Fu2 fragment suffices for full activity of 
the downstream signaling of LGR5. A similar complex structure of RSPO1 Fu1-Fu2 with 
the ectodomain of LGR4 was reported by Wang et al., indicating a common machanism 
of signaling transduction of LGR4, LGR5 and LGR6. (Wang, Huang et al. 2013) 
Unlike other GPCRs, LGR4, LGR5 and LGR6 are not coupled to either G proteins or β-
arrestin when they are stimulated by RSPOs (Carmon, Gong et al. 2011). Instead, upon 
binding RSPOs, they form a physical complex with Wnt receptor Frizzled and its co-
receptor LRP6 to regulate Wnt canonical signaling (de Lau, Barker et al. 2011). LGR5 
itself is also a target gene of the Wnt signaling pathway (Haegebarth and Clevers 2009), 
indicating a feedback loop between the receptor and the Wnt signaling pathway (Figure 
1.9). In the beginning, people believed RSPO-LGR5 acted as an enhancer of Wnt 
signaling pathway (Carmon, Gong et al. 2011, Glinka, Dolde et al. 2011). However, 
recent evidence has shown that RSPO-LGR5 axis is a negative feedback factor of Wnt 
signaling. RSPO-LGR5 can form a supercomplex with LRP6-Fz. Though this can 
transiently increase Wnt signaling activation, eventually it will lead to an enhanced 
internalization and degradation of the receptors (Carmon, Lin et al. 2012, Snyder, 
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Rochelle et al. 2013). The role of LGR5 in regulating Wnt signaling becomes more 
dynamic with the identification of the complex formation between RSPO-LGR5 and two 
Wnt antagonists, ZNRF3 and its homolog RNF43. (Chen, Chen et al. 2013, Peng, de Lau 
et al. 2013, Xie, Zamponi et al. 2013).  The authors believe that RSPO-LGR5 can 
competitively bind with these Wnt antagonists to regulate Wnt signaling activity. As a 
summary of all the findings described previously, LGR5 acts as a negative regulator 
when Wnt signaling is over-activated, while it neutralizes the Wnt antagonists when they 
are redundant. Therefore, other than playing a single role as either an enhancer or an 
inhibitor, LGR5 is more like a buffering molecule whose role is to prevent the Wnt 
signaling pathway from getting over-activated or –under-activated. 
The physiological role of LGR5 during normal intestinal development and tumor 
initiation has been studied for the past decade. Early in 2004, Morita et al. has reported 
that LGR5 null mice suffer a neonatal death and the lethality is associated with 
ankyloglossia and gastrointestinal distension (Morita, Mazerbourg et al. 2004), indicating 
an important functional role of LGR5 in the gastrointestinal development. The possible 
underlying mechanism was first revealed by Garcia and Ghiani et al. in 2009 that LGR5 
deficiency leads to premature Paneth cell differentiation associated with the activation of 
the Wnt signaling pathway. These results supported a possible negative feedback role of 
LGR5 in regulating the over-activated Wnt signaling pathway in normal intestinal 
development (Garcia, Ghiani et al. 2009).  
Nowadays, the concepts regarding normal stem cells and cancer stem cells have 
converged. The relationship between LGR5 and intestinal cancer was first revealed by 
Clevers and Barker’ group, who have successfully identified the molecule as a marker for 
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proliferating adult stem cells in the small intestine in 2007 (Barker, van Es et al. 2007). 
The group also observed that conditional deletion of APC in LGR5-positive stem cells 
but not in LGR5-negative cells led to a rapid growth of large adenomas in mouse small 
intestine (Barker, Ridgway et al. 2009), suggesting that intestinal tumors arise from 
LGR5-positive stem cells.  
However, whether LGR5-positive stem cells are the only origin of colon tumor is still 
under debate. A recent study showed that combination of APC loss and KRAS mutation 
can also initiate tumors from LGR5-negative villus cells (Schwitalla, Fingerle et al. 
2013). Taken together with the colon cancer metastasis theories described in the previous 
section, many cancer researchers believe malignant cells can also arise from the non-stem 
cells lineage. Several clinical studies have evaluated the relationship between expressions 
of certain stem cell markers with the most clinically relevant features of colorectal 
cancer. These results suggest that, despite the increased expression of stem cell markers, 
including EpCAM, CD166, CD44s, ASCL2 and LGR5, it is the overall decreased 
expression of these markers that is linked to a more aggressive tumor phenotype and 
poorer prognosis (Lugli, Iezzi et al. 2010, de Sousa, Colak et al. 2011). This studies 
indicate that those stem cell markers might play a suppressor role in cancer malignancy 
or cancer cells that rising from the other lineages of epithelial cells, other than stem cell 
lineage are responsible for the malignancy of the disease. 
As for LGR5, conflicting reports have been published regarding the functional role of 
LGR5 in colon cancer tumorigenesis. Some studies reported that RSPO-LGR5 signaling 
has a tumor suppressive phenotype in colon cancer (Walker, Zhang et al. 2011, Wu, Qiu 
et al. 2014), whereas others showed that LGR5 promotes tumorigenicity (Tsuji, Kawasaki 
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et al. 2014). The role of LGR5 in colon cancer tumorigenesis remains ambiguous, which 
is likely due to the dual role of RSPO-LGR5 axis in regulating Wnt signaling pathway at 
the onset of the disease. As Wnt signaling is widely and coercively activated after tumor 
initiation, it is yet to be determined whether LGR5 still continuous contributes to the later 
stages of colon cancer progression and metastasis.  
1.2.3 TGFβ  Signaling Pathway 
The transforming growth factor-beta (TGFβ) signaling pathway is a key player in cancer 
biology, and its deregulation can result in tumor development. TGFβ comprises a group 
of multifunctional polypeptides that regulate cellular processes through binding to three 
major TGFβ receptors, type I (RI), type II (RII) and type III (RIII) (Hu, Datto et al. 
1998).  As indicated in Figure 1.10, upon binding TGFβ, RII recruits and activates RI, 
which then phosphorylates and activates Smad2 and Smad3. Activated Smad2 and/or 
Smad3 form complexes with Smad4 and translocate to the nucleus, where they will 
further recruit transcriptional coactivators, corepressors and chromatin remodeling factors 
to regulate gene expression (Massague, Seoane et al. 2005). The expression of each target 
gene is dependent on transcription partner cofactors whose expressions are highly 
restricted by cells type and their environmental condition.  
However, TGFβ activation can also shift to its non-canonical pathway when the signaling 
transduction components in the canonical pathway are impaired.  The non-canonical 
TGFβ signaling includes various branches of MAP kinase (MAPK) pathways, Rho-like 
GTPase signaling pathways and phosphatidylinositol-3-kinase (PI3K)/AKT pathways 
(Zhang 2009). The non-canonical   pathways could mediate the epithelial-mesenchymal 
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transition (EMT) phenotypes or compete with the canonical effects of TGFβ. 
Consequently, the output of a TGFβ response is highly contextual throughout 
development, across different tissues and also in cancer. 
TGFβ is an autocrine-negative growth factor, as evidenced by stimulation of growth of 
several cell lines treated with TGFβ-neutralizing antibody (Arteaga, Coffey et al. 1990, 
Hafez, Infante et al. 1990, Wu, Theodorescu et al. 1992, Wu, Sun et al. 1993, Wang, Han 
et al. 1996, Hu, Datto et al. 1998). Defective TGFβ signaling occurs in 30-50% of colon 
cancer patients and in most of the hyper-mutated tumor type. (Markowitz, Wang et al. 
1995, Grady, Myeroff et al. 1999, Salovaara, Roth et al. 2002, Cancer Genome Atlas 
2012). We and others have demonstrated experimentally that TGFβ mediates tumor 
suppressor activity in a variety of cancers including colon cancer, and that loss of TGFβ 
signaling leads to malignancy (Wu, Theodorescu et al. 1992, Wu, Sun et al. 1993, Sun, 
Wu et al. 1994, Ye, Foster et al. 1999, Wang, Sergina et al. 2004, Veenendaal, 
Kranenburg et al. 2008). For example, transfecting TGFβ1 antisense into the TGFβ 
responsive FET colon cancer cells led to robust malignant progression (Wu, Theodorescu 
et al. 1992, Wu, Sun et al. 1993); Inactivation of TGFβ RII led to increased 
tumorigenicity in athymic mice (Ye, Foster et al. 1999).  In contrast, we demonstrated 
that restoration of TGFβ signaling by ectopic expression of TGFβ receptors (RI or RII) 
resulted in reduced tumorigenicity (Sun, Wu et al. 1994, Wang, Han et al. 1996). Taken 
together, these studies indicate that TGFβ signaling plays an essential role in deterring 
tumor progression in human colon carcinoma cells.  Studies of human tumor samples 
indicate that activity of the TGFβ signaling pathway is reduced in metastatic colon 
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tumors as compared to primary tumors by measuring phospho-Smad2 in a tissue array 
study (Veenendaal, Kranenburg et al. 2008). In addition, another tissue array study of 310 
colon carcinomas show that lower expression of TGFβ1 and loss of nuclear Smad4 
expression are associated with presence of lymph node metastasis (Bacman, Merkel et al. 
2007). These studies indicate that loss or reduction of TGFβ signaling in human colon 
cancer is associated with development of metastasis, and that our studies of TGFβ as a 
metastasis suppressor are relevant to human colon cancer.  
Traditionally, TGFβ's tumor suppressive activity has been attributed to its ability to 
inhibit cell cycle progression. However, its role in apoptosis as a mechanism of tumor 
suppression is under-explored. Our preliminary studies indicate that abrogation of TGFβ 
signaling enables increased survival under GFDS in colon cancer cells. In addition, we 
have shown that loss of TGFβ signaling is associated with increased metastasis, whereas 
enhanced TGFβ signaling suppresses metastasis in an orthotopic model of colon cancer. 
These results suggest that endogenous TGFβ acts as an intrinsic fail-safe mechanism in 
the early stages of carcinogenesis by promoting cell death under stress conditions to 
prevent malignant progression, whereas abrogation of TGFβ signaling leads to activation 
of oncogenic signals that protect tumor cells from apoptosis. However, it is not clear how 
loss of TGFβ signaling leads to resistance to stress-induced apoptosis. Answering these 
questions will provide evidence for new TGFβ tumor suppressor functions that could be 
mimicked by novel treatments. 
In contrast to its tumor suppressor function in colon cancer, TGFβ functions as a tumor 
promoter in other types of cancer including breast cancer. Many studies have shown that 
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TGFβ promotes metastasis in breast cancer (Wakefield and Roberts 2002). However, it 
has been reported that knockout of type II TGFβ receptor in mammary epithelia induced 
tumor formation and promoted metastasis, indicating that TGFβ suppresses metastasis in 
breast cancer (Forrester, Chytil et al. 2005, Yang, Huang et al. 2008)(17;18). The 
contradicting role of TGFβ in metastasis of colon and breast cancer suggests that 
different mechanisms are involved. The metastasis promoting activity of TGFβ in breast 
cancer has been associated with increased motility and invasion, and with induction of an 
epithelial to mesenchymal transition (EMT) (Wakefield and Roberts 2002), which 




Figure 1.7 Canonical Wnt Signaling Pathway.  A. In the absence of Wnt, cytoplasmic 
β-catenin forms a complex with Axin, APC, GSK3 and CK1, and is phosphorylated by 
CK1 (blue) and subsequently by GSK3 (yellow). Phosphorylated β-catenin is recognized 
by the E3 ubiquitin ligase β-Trcp, which targets β- catenin for proteosomal degradation. 
Wnt target genes are repressed by TCF-TLE/Groucho and HDAC. B. In the presence of 
Wnt ligand, a receptor complex forms between Fz and LRP5/6. Dvl recruitment by Fz 
leads to LRP5/6 phosphorylation and Axin recruitment. This disrupts Axin-mediated 
phosphorylation/degradation of β-catenin, allowing β-catenin to accumulate in the 
nucleus where it serves as a co-activator for TCF to activate Wnt responsive genes. 
(MacDonald, Tamai et al. 2009) 




Figure 1.8 LGR5/GPR49 is a G-protein–coupled Receptor Related to the 
Glycoprotein Hormone Receptors. A. Predicted structure of LGR5, containing a large 
extracellular domain with multiple leucine-rich repeats that mediate ligand interaction, a 
7TM domain, and a C-terminal intracellular domain for signal transduction. B. 
Phylogenetic relationship between LGR5 and related family members. The ligands for 
LGR4, LGR5, and LGR6 have not been identified.  (Barker and Clevers 2010) 







Figure 1.9 RSPO-LGR5 Regulation of Wnt Signaling Pathway. A. After binding with 
Wnt-Fz-LRP, RSPO-LGR5 transiently amplify the Wnt signaling and then B. bring the 
whole complex into cytoplasm for degradation. C. RSPO-LGR5 can competitively bind 




Figure 1.10 Canonical TGFβ  Signaling Pathway. TGFβ ligands dimerizes and binds to 
RII and subsequently recruits RI, which is activated by  the phosphorylation of the GS 
domain in the cytoplasmic region. Activated RI further activates smad2/3, which will 
form complex with Smad4, translocate to nucleus and bind to the smad binding elements 
(SBE) on DNA to facilitate target gene transcription.  
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1.3 Study Strategies of Colorectal Cancer Metastasis 
The aforementioned introductions have demonstrated the process of cancer progression 
morphologically and molecularly. The goal of the studies in this dissertation is to reveal 
the role of RSPO-LGR5 axis in colorectal cancer metastasis. Although different theories 
have conflicting views on the origins or the rising routes of metastatic cells, our objective 
is to characterize RSPO-LGR5’s function in regulating malignant properties of colon 
cancer cells and the underlying mechanisms by which altered critical signaling pathways 
drive the metastatic process.  
We manipulated the expression of LGR5 by using shRNA interference to knock down its 
expression and/or using retroviral infection to increase its expression in colon cancer cell 
lines. Cell malignant phenotypes were characterized in vitro and in vivo.  For in vitro 
studies, we characterize the cells’ proliferation, apoptosis and colony/tumor formation 
capability. For in vivo studies, we used an orthotopic transplantation technique to 
determine the metastatic capability of the cells in animal models. Alterations of certain 
genetic molecules were determined by Western Blot, RT-PCR and 
immunohistochemistry (IHC) staining. Cell signaling activity was measured by luciferase 
reporter assay or activation and/ or expression of the signaling effectors or target genes. 
Protein-protein interactions were determined by immuneprecipitation (IP), 
immunofluorescence and confocal microscopy.  
Paraffin embedded human colon cancer specimen were collected from the UNMC tissue 
bank as tissue micro array (TMA) blocks, correlations between interested molecules were 
examined by IHC staining. In silico analysis were perform on the Oncomine, Nexus 














* The Institutional Biosafety Committee (IBC) has approved the protocol of all 
experiments involving hazardous biological materials in the study. 
* The Institutional Animal Care and Use Committee (IACUC) has approved the protocol 
of all the animal experiments in the study. 
* The Institutional Review Board (IRB) has approved the protocol of all the experiments 
involving human subjects in the study. 
2.1  Cell Lines and Cell Culture  
The human colon carcinoma cell lines TENN, RKO, HCT116, HCT116b, CBS and FET 
cells were isolated from human colon cancer patients and established in tissue culture as 
described previously(Brattain, Brattain et al. 1981). Cells were maintained at 37°C in a 
humidified incubator with 5% CO2 and cultured in SM medium (Serum-free McCoy's 5A 
medium; Sigma) supplemented with 10 ng/mL of epidermal growth factor (EGF), 20 
mg/mL of insulin, and 4 mg/mL of transferrin. When cells were under growth factor 
deprivation stress (GFDS), they were cultured in SM medium in the absence of growth 
factor or serum supplements for the indicated time without changing medium in between. 
2.2  Plasmids 
Two LGR5 shRNAs were subcloned into FSIPPW lentiviral vector under the H1 
promoter. The two pLKO.1 lentiviral TGFBR1 shRNA constructs were gifts from Dr. 
Luzhe Sun (University of Texas Health Science Center, TX, USA). Full-length human 
TGFBR2 cDNA was amplified from FET cell and subcloned into the pMX retroviral 
vector. The N-terminal HA-tagged full-length human LGR5 retroviral plasmid was a gift 
from Dr. Keith Johnson (University of Nebraska Medical Center, NE, USA).   
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2.3  Transfection and Stable Cells Establishment 
Transfections were performed using Lipo-fectamine 2000 reagent (Invitrogen) according 
to the manufacturer’s instructions. The lentiviral constructs were co-transfected with two 
lentiviral packaging plasmids pMD2.G and psPAX2 (gifts from Dr. Didier Trono, 
Addgene plasmid #12259 and #12260) into the 293TN cells. The retroviral constructs 
were co-transfected with pVSV.G (a gift from Tannishtha Reya, Addgene Plasmid 
#14888) into 293GP cells. Viruses were harvested at 48h and used to infect cells. Stable 
CBS/FET-LGR5 shRNA knockdown cells, HCT116-TGFBR1 knockdown cells and 
HCT116-TGFBR2 overexpression cells were established under the selection of 2ng/ml 
puromycin for five days. HCT116-LGR5/HA overexpression cells were stably generated 
after one-week selection with 600ng/ml G418. Stable pools were then confirmed by 
western blotting 
 
2.4  Antibodies and Reagents 
LGR5 monoclonal antibody (EPR3065Y) (#ab75850) and phospho-smad2 (Ser465/467) 
(#AB3849) was purchased from Abcam and EMD Millipore respectively.  Ki67 
(#550609) was obtained from BD Biosciences. Cleaved PARP (#5625), smad2/3 
(#8685), smad4 (#9515), TGFBR1 (#3712), TGFBR2 (#11888), LRP6 (#2560), phospho-
LRP6 (Ser1490) (#2588) and beta-actin (#4970) antibodies were obtained from Cell 
Signaling Technology. Recombinant human TGFβ1 and RSPO1-4 were purchased from 
R&D Systems. TGFβ-receptor type I kinase inhibitor (SB525334), salinomycin and 
tharpsigargin were purchased from Sigma-Aldrich.  
The Cell Death Detection ELISA plus kit was from Roche Life Science. ApopTag Plus 
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Peroxidase In Situ Apoptosis Detection kit (TUNEL Assay) was from Millipore. The 
IHC staining kit was from DAKO North America. Hematoxylin and Eosin were obtained 
from Sigma-Aldrich.  
2.5  RT-PCR 
Total RNA was isolated from cell lines or tumor samples using TRIZOL reagent 
(Invitrogen). A total of 2μg of total RNA was reverse-transcribed to cDNA with MLV-
reverse transcriptase (Promega). β-actin was used as endogenous control.  
2.6  Western-Blot Analysis 
Cells were washed three times with cold phosphate buffer saline (PBS) then lysed in 
RIPA buffer (EMD, Millipore) containing 50 mmol/L NaF, 1 mmol/L Na3VO4, 25 
μg/mL β-glycerophosphate, 1 mmol/L phenylmethylsulfonyl fluoride (PMSF) and 
protease inhibitor cocktail (Roche Life Science) for 30 min on ice. For complete lysis, 
sonication was used to disrupt the cell membranes and shear DNA. Cell debris was 
removed by centrifuging the lysate at 1,4000 rpm for 20 min at 4 °C. Protein 
concentration of the supernatant was measured by the BCA protein assay according to the 
manufacture’s instruction (Pierce Biotechnology). After denaturing in 4xSDS sample 
buffer (12% SDS, 25% Glycerol, 150mM Tis-HCl, 0.05% Bromophenol blue, 6% β-
mercaptoethanol), protein lysate was resolved by SDS–polyacrylamide gel 
electrophoresis and transferred to a nitrocellulose membrane (Thermo Scientific). The 
membrane was blocked with 5% non-fat dry milk in PBST (50mM Tris, pH 7.5, 150mM 
NaCl, 0.01% Tween 20) for one hour at room temperature and then incubated with 
primary antibodies for overnight at 4 °C. After three times washing with PBST, the 
membrane was incubated with species-specific horseradish peroxidase-conjugated 
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secondary antibody for 1 hour at room temperature. Super Signal West Pico or Femto 
Chemiluminescent System (Thermo Scientific) was used for protein detection.  
2.7  Immunoprecipitation (IP) 
Cells were lysed and protein concentration was measured as was described previously. 
Immunoprecipitation (IP) was performed with 1mg protein aliquots using magnetic beads 
(PureProteome Protein G or Protein A Magnetic Beads, Millipore). The 1mg protein 
sample was mixed with the primary antibody according to the dilution described in 
manufacture instruction and incubated overnight at 4°C. The following day, 50μL 
suspended beads per IP reaction were aliquot into 1.5 mL microcentrifuge tubes followed 
by three times washing with PBST. The IP samples containing the primary antibody were 
incubated with the washed magnetic beads for 30 minutes at room temperature with 
continuous mixing to generate the IP immune complex. Following pelleting of the beads, 
the IP supernatant fraction was removed to a new tube and stored for further analysis. 
The beads were washed three times with 500μL of PBST. After the final wash, the 
pelleted magnetic beads were re-suspended in 60uL of 1×SDS sample buffer. The 
samples were denatured at 95°C for 10min. The beads were pelleted and the supernatant 
were transferred to a new tube. Proteins in the complex were then detected by Western 
blotting technique.  
2.8  Immunofluorescence (IF) Microscopy 
Immunofluorescence microscopy was performed to visualize the localization of the 
proteins involving the complex formation. Cells were grown on poly-D-lysine–coated 
glass cover slips suitable for immunofluorescence microscopy. Following drug treatment, 
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cells were washed with IF buffer (1% BSA in PBS) and fixed with 4% w/v formaldehyde 
for 20 min at room temperature. Following a 1 min wash with PBS, cells were 
permeabilized with 0.3% Triton X-100 in IF buffer for 15 min. After further washing, the 
cells were blocked with 10% goat serum in IF buffer for 1h at room temperature. Cells 
were then processed with primary antibodies overnight at 4°C, and then washed three 
times for 1min with IF buffer. Secondary antibodies (Invitrogen) conjugated with Alexa 
Fluor 488 and Alexa Fluor 594 was used for staining as appropriate and incubated with 
the cells in the dark. Following washing and DAPI treatment, the cell staining was 
visualized with a Zeiss 710 confocal laser-scanning microscope equipped with 4 lasers: a 
Blue Diode 405nm; an Argon Laser 458/477/488 514nm; a DPSS 561nm and a HeNe 
633nm. The image-processing software such as Zeiss and ImageJ were used for the 
quantitation of the fluorescence and analysis of colocalization, etc 
2.9  MTT Assay 
MTT assay was used to quantify the number of viable cells. Briefly, 50% v/v MTT 
reagent (2% w/v 3-[4,5-Dimethylthiazol-2-yl]-2,5- diphenyltetrazolium bromide) was 
added to each culture well followed by incubation at 37 °C for 2 hours. The medium was 
removed and cells were dissolved in dimethyl sulfoxide (DMSO) followed by a gentle 
shaking for 10 minutes. 200μL dissolvent were then transferred to 96-well plates and the 
absorbance was read at a 570 nm wavelength under the microplate reader (Bio-Rad).  All 
samples were measured in triplicates. 
2.10  Colony Formation and Soft Agarose Assay.  
Colony formation assay was used to measure the cell proliferation capability and 
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anchorage-dependent growth. To perform the assay, cells were seeded in six-well plates 
at 500 cells per well density and colony number was measured by MTT staining after 3 
weeks. Soft agar assay were performed to test the anchorage-independent growth of the 
cells and also to determine the tumorogenesity of the cells in vitro. To perform the 
experiment, 1ml SF medium contained 0.8% soft agar (BD Biosciences) was poured in 
six-well plates as a base layer. Cells were then suspended in SF medium containing 0.4% 
low melting point agarose (Thermo Scientific) and seeded upon the base layer at a 
density of 3000 cells per well. Plates were maintained at 37°C in a humidified incubator. 
Colonies were stained by 1% w/v iodonitrotetrazolium violet (Sigma-Aldrich) after 3 
weeks and the numbers of colonies were counted under a microscope. All experiments 
were conducted in triplicates. 
2.11  Cell Apoptosis Assay 
Cell apoptosis was measured by DNA fragmentation assay (cell death ELISA assay). 
Cells were seeded in 96-well plates and allowed to grow to 80% confluence. The cells 
were then changed to SM medium for GFDS culture for 2-5 days as was indicated in each 
of the experiments. Apoptosis measurement was then performed using a cell death 
ELISA kit (Roche Life Science) as described in the manufacturer's protocol. DNA 
fragments were measured on the quantitative “sandwich enzyme immunoassay” 
principle. Briefly, anti-DNA-peroxidase (POD) reacted with the DNA fragments in the 
cell lysate. Histone contained DNA fragments were then captured by the anti-histone 
antibody coated on the ELISA plates. With the presence of HRP substrate (ABTS, 2,2'-
Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt substrate), the DNA 
fragments-POD complexes were detected under the absorbance reader at a 405 nm 
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wavelength. The viable cell number was measured by MTT staining to normalize the 
assay.  The ratio of OD 405 / OD 570 is directly proportional to the number of the 
apoptotic cells in the culture. All experiments were conducted in triplicates. 
2.12  Luciferase Reporter Assay 
Luciferase reporter assay was used to determine the Wnt or TGFβ signaling activity in 
different cell lines or with different ligand treatment. To test Wnt activity, a TOPFlash 
plasmid (EMD Millipore) that contains two sets of three copies of the wild-type TCF 
binding regions before the luciferase expression gene were transiently transfected to the 
cells. Respectively, an SBE4-Luc (Addgene plasmid # 16495) plasmid that contains four 
copies of smads-binding elements (SBE4) before the luciferase expression gene were 
transfected into the cells for the detection of TGFβ activity. The pRL-CMV (Promega) 
plasmid that constitutively expresses the renilla gene was used as an internal control. To 
perform the experiment, 8000 cells per well were seeded in 96-well the day before 
transfection. TOPFlash or SBE4-Luc was co-transfected with the pRL-CMV and cells 
were maintained in culture for 2-3 days as was indicated in the experiments. Luciferase 
activity measurements were performed using the Dual Luciferase Assay System 
(Promega). The luminescent signals of firefly and renilla were read under the BioTek 
Synergy MX Reader according to the manufacture instruction. All experiments were 
conducted in triplicates. 
2.13  In Vivo Orthotopic Transplantation 
Orthotopic mouse model of colon cancer has been well established to represent the 
human colon cancer progression and metastasis. Two techniques have been widely used 
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to establish the model. One technique involves injection of a colon cancer cell suspension 
into the cecal wall. The other technique involves transplantation of a piece of 
subcutaneous tumor onto the cecum. Both techniques are similar and require mouse 
anesthesia and laparotomy for exposure of the cecum. In our study, we have used the 
later technique due to the reason that the subcutaneous tumor can introduce a more 
heterogeneous population of cancer cells that has been established in xenograft model, 
which better represents the nature property of primary tumors in human colon cancer 
disease. 
 
To start with, the control and LGR5 knockdown CBS cells were stably transfected with 
GFP construct. Exponentially growing GFP-labeled cells (5x106) were inoculated 
subcutaneously onto the dorsal surfaces of the athymic nude mice (Harlan Laboratories). 
Once xenografts were established (~ 5 weeks post-inoculation), mice were terminated 
and tumors were excised into 1mm3 pieces. For implantation procedures, animals were 
anesthetized with isoflurane inhalation. A 1cm laparotomy was done for the 
exteriorization of the cecum and ascending colon of the animal. The serosa was disrupted 
at two locations of the cecum. Two pieces of xenograft were positioned and sub-serosally 
implanted using an 8-0 nylon suture at the disrupted serosal locations. The bowel was 
then returned to the peritoneal cavity and the abdomen was closed with 5-0 vicryl sutures.  
Buprenex was delivered to the animal three times a day at the dose of 0.1mg/kg for three 
days post-surgery. Fluorescence imaging was performed weekly to follow tumor growth 
and progression (LightTools).  Around seventy days post-implantation, animals were 
euthanized. Organs were explanted, imaged, and immediately placed in buffered 10% 
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formalin. Tissues were then processed and embedded in paraffin. Slides were cut for 
H&E and IHC staining.  
2.14  Hematoxylin and Eosin (H&E) and Immunohistochemistry (IHC)  
Formalin-fixed paraffin-embedded tissue blocks of primary tumor, liver and lung were 
made as was described previously and sectioned for further analysis. Distal metastasis to 
liver and lung were evaluated from the H&E staining of liver and lung tissue; Local 
invasiveness and lymph tubular metastases were also evaluated from the H&E staining of 
primary tumor. IHC staining of TUNEL, Ki67 and pSmad2 expression were performed in 
the primary tumor sections. TUNEL assays were performed using ApopTag Peroxidase 
In Situ Oligo Ligation Apoptosis Detection Kit (Millipore). The sources of primary 
antibodies used for IHC are: Ki67 (BD Pharmingen) and pSmad2 (Cell Signaling 
Technology). Tissue slides were subjected to antigen retrieval using Novocastra Epitope 
Retrieval Solutions, pH 6 (Leica), followed by incubation with primary antibodies at 4°C 
overnight. A biotin goat anti-mouse and -rabbit secondary antibody (BD Pharmingen) 
was used for Ki67 and pSmad2, respectively, followed by incubation with streptavidin-
horseradish-peroxidase (BD Pharmingen). Apoptosis and proliferation were determined 
quantitatively by counting the number of positively stained cells for TUNEL and Ki67 at 
×20 magnification. Staining density of pSmad2 was quantified with Imagescope Software 
(Leica Biosystems). 4-6 animals were analyzed for each cell type. Ten histologically 
fields were randomly selected from each section for analysis.  
 
2.15  Ex Vivo Intestinal Crypt Culture 
In recent years, protocols for growing organoids containing crypts and villus from adult 
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mouse intestinal epithelium in matrigel have been widely developed. As the crypts 
directly isolated from mouse can be maintained in culture for years, this model has 
proven to serve as a powerful system to investigate regulatory and pathological 
mechanisms of the intestinal epithelium on both cellular level and molecular level.  
In our study, intestinal crypts from wide-type and Apcmin/+ mouse were isolated according 
to the methods described in previous publications (Barker, Ridgway et al. 2009, Sato, 
Vries et al. 2009). Briefly, crypts were released from mouse small intestine by incubation 
for 30 min at 4 °C in PBS containing 2 mM EDTA. Followed by a few steps of wash and 
centrifugation, isolated crypts were counted and pelleted. A total of 500 to 1000 crypts 
were mixed with 50 ml of Matrigel (BD Bioscience) and plated in 24-well plates. After 
polymerization of Matrigel, 500µl of DMEM/ F12 medium containing N2 supplement, 
B27 supplement (Gibco), 1 μM N-acetyl cysteine, 10 mM Hepes, glutamine, 
penicillin/streptomycin (Sigma-Aldrich), 100 ng/mL mNoggin, 50 ng/mL mEGF, and 
500 ng/mL mRSPO1 (R&D Systems) were added to each well. Culture medium 
containing the growth factors was changed every 4 days. For passaging the culture, 
organoids were removed from Matrigel and mechanically dissociated into single-crypt 
domains, and then transferred to fresh Matrigel. Passage was performed every 1–2 weeks 
with 1:2 and 1:5 split ratios for wide-type and Apcmin/- organoids, respectively. Intestinal 
crypts from Apcmin/+ were initially cultured without mRSPO1. Under these conditions, 




2.16  Conditional Medium 
To produce conditional medium containing active RSPO1 ligands, the expression vector 
inserted with the RSPO1 recombinant cDNA was stably introduced into HEK293 cells. 
To harvest the conditional medium, 1×106 cells were plated in 10 mL culture medium in 
the 10 cm tissue culture dishes or T­75 flasks and grown for 4 days (approximately to 
confluency). ! Take off the medium and sterile filter to collect the first batch of medium, 
then add 10 mL fresh culture medium and culture for another 3 days to collect the second 
batch of medium. Mix the first and the second batch with 1:1 ratio as working medium. 
2.17  Statistical Analyses.  
The data represent the mean ± SEM. Statistical comparisons were performed using 
Student’s t-test. Unless otherwise indicated. A P-value < 0.05 was considered to be 

















LGR5 Inhibit Colon Cancer Metastasis Through the 
Activation of TGFβ  Signaling Pathway 
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3.1 LGR5 expression inversely correlates with colon cancer tumor stages. 
As introduced in the previous chapters, several studies have shown that expression of 
LGR5 decreases during colon cancer progression (de Sousa, Colak et al. 2011) and that 
re-expression of LGR5 or its ligands RSPOs suppresses tumor formation (de Sousa, 
Colak et al. 2011, Walker, Zhang et al. 2011, Wu, Qiu et al. 2014). To confirm these 
findings, we have assessed copy number variation (CNV) of LGR5 from the Cancer 
Genome Atlas (TCGA) on 445 cases of colon primary tumors. The data suggest that 
CNV loss of LGR5 is enriched in late stage colon cancer stage III patients and with high 
lymph node spread and/or distant metastasis (P < 0.05) (Table 3.1). More importantly, 
LGR5 CNV loss correlates with poor survival probability of colon cancer patients (P = 
0.08) (Figure 3.1A).  
Although the loss of LGR5 DNA copy number associates with late stage colon cancer 
and the event is enriched in patients with poor survival, it is not known whether 
expression of LGR5 shows the same correlation. We therefore determined expression of 
LGR5 in primary tumors of different cancer type and different tumor stages. A 
comparison of the LGR5 mRNA expression between normal colon, colon adenomas and 
carcinomas was performed in the Oncomine® Research Edition platform. The analysis 
showed that although LGR5 mRNA expression is higher in adenomas and carcinomas 
than in normal controls, its expression decreases in carcinomas when compared to 
adenomas. (Figure 3.1B). These data suggest that LGR5 expression may increase during 
the onset of colon tumorigenesis and decrease thereafter during tumor progression. We 
therefore hypothesized that LGR5 expression inversely correlates with advanced stages in 
human colon tumors. To test this hypothesis, we examined LGR5 protein expression in 
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tissue samples from normal colon and colon cancer patients at stage I, II or IV. IHC 
staining results revealed that expression of LGR5 in adenocarcinomas of stage I and II 
was statistically higher than that in normal colonic epithelial cells (Figure 3.1C). 
However, there was a significant decrease in LGR5 expression in stage IV tumors as 
compared to those of stages I or II. The percentage of LGR5 positive cells and the 
intensity of the staining in individual tissue samples are shown in Figure 3.1D&E. These 
results indicate that LGR5 expression increases during the onset of colon tumorigenesis 
and decrease thereafter during tumor progression.  
Additionally, LGR5 is differentially expressed in  colon cancer cell lines. Examination of 
LGR5 protein and mRNA expression in human colon cancer cell lines showed that highly 
metastatic cell lines such HCT116, RKO and TENN cells express lower amounts of 
LGR5 than moderately, weakly or non-metastatic CBS, HCT116b and FET cells 
respectively at both protein and mRNA levels (Figure 3.1F), indicating an inverse 




Table 3.1 Enrichment Analysis of LGR5 CNV Loss in Primary Tumor with 
Different Lymph Node Metastasis and TNM Stages of the Individuals. Patients’ 
information and DNA copy number of total 466 cases of colon cancer was obtained from 
TCGA database. The DNA copy number variation (CNV) and enrichment analysis were 
generated on Nexus Copy Number software, BioDiscovery. LGR5 CNV loss is enriched 




Figure 3.1A LGR5 CNV Inversely Correlates with Patients Survival Rate. K-M 
analysis for LGR5 CNV loss in colon cancer patients was performed on Nexus Copy 
Number software, BioDiscovery. LGR5 CNV loss (green line) has less survival 












Figure 3.1B LGR5 Expression Inversely Correlates with Tumor Grade. Comparison 
analysis of LGR5 mRNA expression between normal to adenoma, and to carcinoma was 
performed on Oncomine data analysis platform based on the Skrzypczak Colorectal 2 
dataset. LGR5 mRNA expression increases in adenoma by 30 fold comparing to normal 































Figure 3.1 C-E LGR5 Expression Inversely Correlates with Cancer Stages. C. 
Immunohistochemistry staining with LGR5 antibody on different stages of primary colon 
cancer sections. D. Plots of percentage of LGR5 positive cells in each of the individual 
sections E. Plots of intensity of LGR5 staining in each of the individual sections. Error 
bars indicate SEM of all samples. Statistical significance was determined by Student’s t-
test. (* P < 0.05, ** P < 0.001, n = 9 in stage I, 10 in normal, stage II and IV)  
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Figure 3.1F LGR5 Expression Inversely Correlates with Metastatic Potential in 
Colon Cancer Cell Lines. Top panel shows protein expression of LGR5 in different 
colon cell lines by Western blotting. Middle panel shows mRNA level of LGR5 in colon 
cancer cell lines by RT-PCR. Cells were grouped into highly metastatic (red) and low or 
non-metastatic (black). Bottom panel shows relative expression of LGR5 in each of the 
cell line and the comparison between highly metastatic versus low metastatic group. 
Quantification was performed by imageJ. Error bars indicate SEM of all samples. 
Statistical significance was determined by Student’s t-test.  (*** P < 0.001, n = 6 of 
highly metastatic protein samples; 5 of highly metastatic mRNA samples; 7 of low 







































































3.2 LGR5 Inhibits Colon Cancer Malignant Phenotypes in vitro.  
Results from last section promoted us to explore whether LGR5 might play a suppressive 
role in colon cancer progression and metastasis. Accordingly, LGR5 expression was 
knocked down in FET and CBS cells using shRNAs. Expression of LGR5 was reduced 
by more than 90% with each of the two independent shRNAs (#5 and #6) (Figure 3.2A). 
Since aberrant survival capacity of tumor cells is an important determinant of metastatic 
potential, we first evaluated the ability of colon cancer cells to withstand stress-induced 
apoptosis in vitro. Under growth factor and nutrient deprivation stress (GFDS), LGR5 
knockdown cells showed increased resistance to GFDS-induced apoptosis as reflected by 
decreased PARP cleavage (Figure 3.2A) and reduced apoptosis in DNA fragmentation 
assays (Figure 3.2B), indicating that LGR5 mediates stress-induced apoptosis. In 
addition, colony formation assays in adhesion and in soft agar indicated that knockdown 
of LGR5 expression led to almost 2 fold of increase in colony forming capacity when 
plated at sparse densities (Figure 3.2C) and 2.5 – 4.5 fold of increase in anchorage-
independent growth (Figure 3.2D). These results demonstrate that knockdown of LGR5 
expression increases cell survival and clonogenecity in vitro.  
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Figure 3.2A&B LGR5 Contributes to GFDS-induced Apoptosis. Two LGR5 shRNAs 
and their corresponding scramble control were introduced in FET cells and CBS cells 
(A). Western blot analysis of poly ADP ribose polymerase (PARP) was performed in 
FET and CBS cells under GFDS for 48 hours. DNA fragmentation assays were 
performed (B). Error bars indicate SEM of three replications. Statistical significance was 
determined by Student’s t-test.  *** P < 0.001 
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Figure 3.2C&D LGR5 Affects Cancer Cell Tumorigenicity in vitro. Knock down of 
LGR5 increases cell colony formation as shown in (C). Knock down cells as well as their 
control cells were plated at 500/well in 6-well plate and stained with MTT at day 14. 
Plates were scanned and cells were dissolved in DMSO and read at OD 570 nm. Knock 
down of LGR5 also increases cell anchorage-independent growth (D). 3000/well of cells 
were seeded in 0.4% soft agar with a lower layer of 0.8% soft agar and stained with 
0.01% iodonitrotetrazolium violet at Day 25. A-F. Error bars indicate SEM of three 
replications. Statistical significance was determined by Student’s t-test.  ** P < 0.01, *** 
























































3.3 LGR5 Inhibits Colon Cancer Metastasis in vivo. 
We next examined the role of LGR5 in colon cancer metastasis using an orthotopic 
mouse model that recapitulates human colon cancer metastasis to the liver and lungs 
(Guo, Rajput et al. 2007, Jiang, Liu et al. 2011). We used CBS cells with LGR5 
knockdown for this study since CBS cells are moderately metastatic in vivo (Simms, 
Rajput et al. 2012). Mice implanted with CBS control or LGR5 knockdown cells (LGR5 
KD: combined results of two shRNAs) showed 100% primary tumor growth. Although 
knockdown of LGR5 expression resulted in a 23% increase in primary tumor weight 
(Figure 3.3D), it also significantly increased the incidence of liver and/or lung metastasis 
from 29% to 78% (Table 3.3). Fluorescence imaging of explanted liver or lungs showed 
increased tumor burden of metastases in mice implanted with LGR5 KD cells (Figure 
3.3A). To confirm GFP imaging results, RNA was extracted from lungs and liver of each 
mouse and semi-quantitative RT-PCR was performed using a human specific GAPDH 
primer. The level of human GAPDH mRNA expression in each sample represents the 
amount of human RNA, which is a reflection of tumor burden in the lungs and livers of 
the mice. RT-PCR results showed that the human specific GAPDH mRNA level was 
much higher in LGR5 KD group than in the control group (Figure 3.3B&C). These 
results indicate LGR5 inhibits incidence and tumor burden of colon cancer metastasis in 
vivo.  
To determine whether LGR5-mediated cell proliferation and apoptosis were associated 
with its regulation of metastatic potential in vivo, TUNEL and Ki67 assays were 
performed. TUNEL staining of primary tumors showed that there were significantly 
fewer apoptotic cells in the tumors of LGR5 KD cells than in those of control cells (8.5% 
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vs. 29.2%, Figure 3.3F). Meanwhile Ki67 staining showed that tumors of LGR5 KD 
cells also had higher percentage of proliferative cells than those of control cells (95.7% 
vs. 65.8%, Figure 3.3E). These results indicate that the inhibitory effect of LGR5 on 
metastasis was a result of its combined effect on suppression of cell proliferation and 





Table 3.3 Summary of Liver and Lung Metastasis of Control and LGR5 
Knockdown Cells 
 
Percentage of metastasis to either liver or lung was calculated. Statistical significance 
was determined by Fisher Exact test. ** P < 0.01. Power > 80% 
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Figure 3.3A-D Reduction of LGR5 Increases Colon Cancer Metastasis. A. Green 
fluorescent protein (GFP) images of liver and lung metastasis are shown in the upper 
panel.  Representatives of H&E staining of liver and lung were shown in the lower panel. 
Tumors were indicated by arrows. B&C. Number of metastasis cases was determined by 
semi-quantification of human specific GAPDH in liver and lung. Summary of metastasis 
cases were calculated in Table 3.3. D. Primary tumor weight of individual animal was 
plotted in the upper panel. Error bars indicate SEM of samples in each group. The 
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Figure 3.3E&F. LGR5 Regulates Cell Proliferation and Apoptosis in vivo. Images of 
Ki67 (E, ×20 magnification) and TUNEL (F, ×20 magnification) staining of primary 
tumors are shown in the upper panels. The images are representative of multiple fields of 
tumor sections from six tumors per group. Numbers of positive Ki67 and TUNEL 
staining cells were determined under the Imagescope software. The data are presented as 
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3.4 LGR5 activates TGFβ signaling in colon cancer cells.  
To determine the mechanisms of LGR5 function, we investigated the effect of LGR5 on 
markers related to cell cycle and apoptosis. We found that LGR5 can regulate cyclin D1, 
p21, p27 and pAKT (Figure 3.4H), which all have been reported to be regulated by 
TGFβ signaling pathway (Datto, Li et al. 1995, Ko, Sheng et al. 1995). These findings 
promote us to look into the relationship between LGR5 and TGFβ signaling pathway. 
We used a luciferase plasmid containing multiple Smad binding elements (pSBE4-Luc) 
as a surrogate to determine TGFβ promoter activity. HCT116 cells express undetectable 
TGFβ RII due to mutations caused by microsatellite instability, and re-expression of RII 
in those cells (HCT116-RII) restores their responsiveness to TGFβ (Markowitz, Wang et 
al. 1995, Wang, Sun et al. 1995).  Since HCT116 cells express low levels of LGR5 
(Figure 3.1C), LGR5 expression vector was transfected into those cells. Ectopic 
expression of LGR5 activated TGFβ signaling, as reflected by the luciferase reporter 
activity, in a dose-dependent manner in both HCT116 and HCT116-RII cells, with higher 
activation in HCT116-RII cells (Figure 3.4A upper panel). Expression of p21, a TGFβ 
target gene, was also induced by LGR5 (Figure 3.4A lower panel, Figure 3.4H), 
confirming the activation of the pathway. Exposure of cells to RSPO1 further increased 
LGR5-mediated activation of TGFβ promoter, whereas treatment with a RSPO1 
neutralizing antibody almost completely blocked LGR5 effect (Figure 3.4B). The human 
RSPO1 neutralizing antibody is antigen affinity-purified and displays less than 1% cross-
reactivity with other human RSPOs (R&D Systems). Therefore, these results indicate that 
RSPO1 is primarily responsible for LGR5-mediated TGFβ activation. In the following 
studies, RSPO1 was used to activate LGR5 function. 
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Complementarily, LGR5 expression was knocked down by two different shRNAs in FET 
and CBS cells (Figure 3.2A), which display high levels of endogenous TGFβ activity. 
This resulted in decreased TGFβ promoter activity (Figure 3.4C). In addition, treatment 
of FET and CBS cells with RSPO1 increased TGFβ promoter activity to a similar level as 
that with TGFβ. Treatment with TGFβ and RSPO1 simultaneously induced a much 
higher increase in TGFβ promoter activity than that of either one alone (Figure 3.4D). A 
time course study showed that RSPO1 and TGFβ activate Smad2 with similar dynamics 
in FET cells (Figure 3.4F). These studies indicate that RSPO-LGR5 activates the 
canonical TGFβ pathway in colon cancer cells. 
Since LGR5 activated TGFβ promoter in the absence of TGFβ RII (Figure 3.4A), we 
next determined whether TGFβ RI is required. A potent and selective inhibitor of TGFβ 
RI kinase, SB525334, was used in the following studies. The luciferase reporter assays 
showed that RI kinase inhibitor blocked the activation of TGFβ promoter by RSPO1 
treatment in FET and CBS cells (Figure 3.4D) and by LGR5 expression in HCT116 cells 
(Figure 3.4E), indicating that the kinase activity of TGFβ RI is essential for RSPO1-
LGR5-mediated TGFβ activation. To further determine which Smads play a role in this 
activation, expression of Smad2, Smad3 and Smad4 was knocked down individually by 
shRNAs in FET cells (Figure 3.4G, upper panel). Knockdown of Smad2, Smad3 or 
Smad4 attenuated RSPO1-LGR5-mediated activation of TGFβ signaling as reflected by 
reduction in fold change of luciferase reporter activity induced by RSPO1 treatment 
(Figure 3.4G, lower panel). These results indicate that Smad2, Smad3 and Smad4 are 




Figure 3.4A-C LGR5 Induces TGFβ  Signaling Pathway. A. LGR5 induces TGFβ 
signaling pathway in HCT116 cells with or without TGFβRII. Upper panel, TGFβ 
reporter assay in HCT116 and HCT116RII cells transfected with different dose of LGR5 
expression plasmid (0, 25, 50 and 100ng). ** P <0.01, *** P < 0.001 versus 0 ng group. 
Lower panel, RT-PCR of p21 in control and LGR5 overexpression HCT116 cells. B. 
TGFβ reporter assay in HCT116 control and LGR5 overexpression cells with 500ng/ml 
RSPO1 and RSPO1 neutralizing antibody treatment for 48 hours. C. TGFβ reporter assay 
in FET and CBS LGR5 knock down cells (by scramble control, shRNA#5 and #6). *** P 
< 0.001 versus control group. A-C. Error bars indicate the SEM of three replications. 
Statistical significance was determined by ANOVA test.   
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Figure 3.4  
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Figure 3.4D-G LGR5-induced TGFβ  Signaling Activation is Mediated by TGFβRI 
Kinase and Smads Activation. D. TGFβ reporter assay in FET and CBS cells following 
500ng/ml RSPO1, 4ng/ml TGFβ and/or 200nM TGFβRI kinase inhibitor (SB525334) 
treatment for 48 hours. E. TGFβ reporter assay in HCT116 vector control and LGR5/HA 
overexpression cells following 200nM SB525334 treatment for 48 hours.  F. Western 
Blot of pSmad2 with 200ng/ml RSPO1 or 4ng/ml TGFβ treatment by time course. G. 
Smad 2,3 and 4 shRNA were stably introduced into FET cells. Expression of Smad 2,3 
and 4 were determined by Western blotting (upper panel). TGFβ signaling activity in 
those cells was measured by reporter assay (lower panel). D&E. Error bars indicate the 
SEM of three replications. Statistical significance was determined by Student’s t-test,  
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Figure 3.4H LGR5 Regulates TGFβ  Signaling Target Genes. pAKT, CyclinD1, p27 
and p21 expression were determined by Western blotting in LGR5 expression-modulated 
cells. Left panel, FET scramble control versus LGR5 knockdown cells; middle panel, 
CBS scramble control versus LGR5 knockdown cells; right panel, HCT116 vector 








3.5 RSPO1-LGR5 Regulates Cellular Functions of Colon Cancer Cells Through 
TGFβ Signaling Pathway. 
When HA-tagged LGR5 (LGR5-HA) was introduced into HCT116 and CBS cells that 
show low and intermediate levels of endogenous LGR5 respectively (Figure 3.1C). 
LGR5 expression was significantly increased (Figure 3.5A) in these two cell lines. 
LGR5-expressing cells became more sensitive to GFDS-induced apoptosis than the 
control cells as reflected by increased caspase-9 cleavage (Figure 3.5A) and induced 
apoptosis in DNA fragmentation assays (Figure 3.5B). Furthermore, overexpression of 
LGR5 reduced clonogenecity in colony formation (Figure 3.5C&E) and soft agarose 
(Figure 3.5D&F) assays. Of note, expression of non-tagged LGR5 showed similar effect 
as HA-tagged LGR5 in HCT116 cells (Data not shown), indicating that HA tag does not 
affect LGR5 function.  
To determine whether LGR5 functions through the activation of TGFβ signaling, the RI 
kinase inhibitor, SB525334, was used in the studies to block the downstream activity. As 
shown in Figure 3.5B,C&D, the RI kinase inhibitor almost completely reversed the 
effect of LGR5 on cell survival and clonogenecity in HCT116 cells. Furthermore, when 
FET cells were treated with RSPO1, it increased GFDS-induced apoptosis and reduced 
clonogenecity in soft agarose to the similar degree as TGFβ (Figure 3.5H). When the RI 
kinase inhibitor was used, it almost completely reversed RSPO1 effects. To show the 
specificity of the RI kinase inhibitor, RI expression was knocked down by an shRNA 
(Figure 3.5I, upper panel). Reduction in RI expression abrogated TGFβ or RSPO1-
mediated induction of apoptosis (Figure 3.5I lower panel) and inhibition of colony 
formation in soft agarose (Figure 3.5J). Taken together, these data indicate that RSPO1-
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LGR5 increases stress-induced apoptosis and inhibits clonogenecity through the 
activation of the TGFβ signaling pathway.  
TGFβ has been shown to suppress metastasis of colon cancer cells in an orthotopic model 
(Barker, van Es et al. 2007, Snippert, Haegebarth et al. 2010, Barker, Rookmaaker et al. 
2012). We have shown in this study that knockdown of LGR5 increased liver and lung 
metastasis of colon cancer cells in vivo (Figure. 3.3). To determine whether LGR5 
mediates TGFβ signaling in vivo, Smad2 phosphorylation was determined in the primary 
tumors of LGR5 KD and control cells. IHC analyses using an anti-phospho-Smad2 
antibody showed that nuclear Smad2 phosphorylation was significantly reduced in the 
primary tumors of LGR5 KD cells as compared to those of the control cells (Figure 3.5F, 
upper panel). Quantification of staining intensity of nuclear pSmad2 indicated that 
TGFβ signaling was inhibited in the tumors of LGR5 KD cells (Figure 3.5F, lower 
panel). These results suggest that LGR5 may suppress colon cancer metastasis through 
the regulation of TGFβ signaling pathway. Similar effects were observed in ex vivo 
organoids culture. RSPO1 or TGFβ could inhibit the growth of Apcmin/+ organoids 
(Figure 3.5G) and activate pSmad2 and pLRP6 (Figure 3.5H). 
Results in this chapter indicate that expression of LGR5 increases early in colon cancer 
development but decreases during colon cancer progression. in vitro and in vivo results in 
colon cancer cells further demonstrate that LGR5, associating with TGFβ signaling, plays 
an important role in colon cancer progression. In addition, the stage-dependent decrease 
of LGR5 expression suggests that LGR5 expression could be used as a potential 
biomarker to predict metastasis in colon cancer.  
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Figure 3.5A&B RI Kinase Inhibitor Abrogates LGR5-induced Apoptosis. HA-
tagged LGR5 expression vector were stably introduced in HCT116 cells and CBS cells 
(A). Western blot analysis of cleaved caspase 9 was performed after GFDS in HCT116 
cell for 96 hours and in CBS cells for 48 hours. 200nM RI kinase inhibitor was applied 
one hour before GFDS and maintained in culture for 96 hours in HCT116 cells. DNA 
fragmentation assays (B) were performed as was described in material and methods. 
Error bars indicate SEM of three replications. Statistical significance was determined by 










































Figure 3.5C-E RI Kinase Inhibitor Abrogates LGR5-induced Clonogenecity 
Suppression.  C and E. LGR5 overexpression cells as well as their control cells were 
plated at 500/well in 6-well plate, 200nM RI inhibitor was applied in HCT116 cells and 
maintained in culture for two weeks. Cells were stained by MTT on day 14, dissolved in 
DMSO and read at OD 570 nm. D and F. 3000/well of cells were seeded in 0.4% soft 
agar. 200nM RI inhibitor was applied in HCT116 cells and maintained in culture for 3 
weeks. Cells were stained with 0.01% crystal violet on day 25. C-F. Error bars indicate 
SEM of three replications. Statistical significance was determined by Student’s t-test.  ** 
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Figure 3.5G&H. RI Kinase Inhibitor Attenuates RSPO1-induced Apoptosis and 
Clonogenecity Suppression in FET Cells. G. Cells were pretreated with 200nM RI 
kinase inhibitor or DMSO one hour before starting GFDS. 500ng/ml RSPO1 or 5ng/ml 
TGFβ were applied in followed by DNA fragmentation assay after 16 hours GFDS. H. 
3000/well of cells were seeded in 0.4% soft agarose. 200nM RI kinase inhibitor, 
500ng/ml RSPO1 or 5ng/ml TGFβ were applied and maintained in culture for 3 weeks. 
Cells were stained with 1% w/v iodonitrotetrazolium violet at Day 25. G&H. Error bars 
indicate SEM of three replications. Statistical significance was determined by Student’s t-






















































Figure 3.5 I&J. RSPO1-induced Cell Apoptosis and Clonogenecity Suppression 
Associate with TGFβ  RI. I. FET cells were stably transfected with TGFβ RI shRNA. 
The expression of RI was determined by Western blotting (upper panel). DNA 
fragmentation assay was performed after 16 hours GFDS (lower panel). J. 3000/well of 
cells were seeded in 0.4% soft agarose and were stained with 1% iodonitrotetrazolium 
violet at Day 25. I&J.  Error bars indicate SEM of three replications. Statistical 































































Figure 3.5F.  Knockdown of LGR5 Associates with Reduced TGFβ  Signaling in 
vivo. Images of pSmad2 staining in primary tumors are shown in the upper panel. The 
images are representative of multiple fields of tumor sections from each group. Intensity 
of positive and strong positive staining cells was determined under the Imagescope 
software. Relative intensity was calculated as percentage of strong positive to all positive 
fields in each section.  The data are normalized as fold change and presented as the mean 
± SEM. n = 7 in control group; 4 in LGR5 KD group. Statistical significance was 






                           Control                                                          LGR5 KD 





























Figure 3.5G&H. RSPO1 Activates TGFβ  Signaling ex vivo. G. 500ng/ml RSPO1 or 
4ng/ml TGFβ was applied to the APCmin/+ organoids for 2 days.  Bright field images were 
taken under 4 x magnifications. Scale bar indicates 1000 μm. H. Lysate of APCmin/+ 
organoids was collected after treating with 500ng/ml RSPO or 4ng/ml TGFβ for 1 hour 



















LGR5 Associates with TGFβ  Receptors and Mediates 
Downstream TGFβ  Signaling Pathway  
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4.1 LGR5 Forms Complex with TGFβ Receptors.  
TGFβ has been shown to bind TGFβ RII, which then associates with RI to transduce 
downstream signaling (Massague, Seoane et al. 2005). To determine the mechanism by 
which RSPO1-LGR5 activates TGFβ signaling, we investigated whether LGR5 forms 
complexes with TGFβ RI and/or RII. To facilitate co-immunoprecipitation (co-IP) assays 
and immunofluorescence staining to detect complex formation and co-localization, we 
used HCT116 cells that express abundant TGFβ RI, no TGFβ RII and little LGR5 to 
construct a stable cell line expressing Flag-tagged TGFβ RII and HA-tagged LGR5 
(HCT116/RII/LGR5). As shown in Figure 4.1, RII/LGR5 cells expressed increased 
amount of RII and LGR5 as compared to the vector control cells. Endogenous RI was 
abundantly expressed in those cells. Co-IP results showed that LGR5, RI and RII all 
could be pulled-down together by targeting any of them, indicating the three receptors 





Figure 4.1 LGR5 Forms Complex with TGFβ Receptors. HCT116 cells were stably 
transfected with Flag-tagged TGFβRII and LGR5 (HCT116/RII/LGR5). From left to 
right panel: Detection of LGR5, RII and RI expression in control and overexpression 
cells by anti-LGR5, RI and RII antibody; Immunoprecipitation (IP) of LGR5 with LGR5 
antibody followed by immunoblotting (IB) with anti-RII and -RI antibodies; IP of RII 
with Flag antibody followed by IB with anti-LGR5 and -RI antibodies; IP of RI with RI 
antibody followed by IB with anti-LGR5 and -RII antibodies. 













4.2 RSPO-LGR5 Mediates TGFβ Signaling by Enhancing the Complex Formation 
with TGFβ  Receptors.  
We then determined whether RSPO1 or TGFβ treatment would induce complex 
formation between LGR5 and TGFβ receptors in RII/LGR5 cells. Treatment of 
HCT116/RII/LGR5 cells with RSPO1 or TGFβ showed an increased Smad2 
phosphorylation (Figure 4.2A). Protein lysates from the control, RSPO1 or TGFβ-treated 
cells were immunoprecipitated with anti-LGR5, anti-RI or anti-RII antibody followed by 
western blot analysis of expression of LGR5, RI and RII in the immunoprecipitated 
complexes. Co-IP results showed that RSPO1 or TGFβ increased the amount of RI and 
RII, LGR5 and RII, LGR5 and RI associated with LGR5, RI or RII respectively (Figure 
4.2A).  These results indicated that treatment with RSPO1 or TGFβ induced the complex 
formation between LGR5 and RI/RII.  
To further confirm the formation of the LGR5/RI/RII complex, immunofluorescence 
microscopy was used to determine whether LGR5 co-localized with TGFβ RI and RII. 
HCT116/LGR5/RII cells treated with RSPO1 or TGFβ were labeled with anti-HA (for 
LGR5), anti-RI or anti-Flag (for RII) antibody followed by incubation with a second 
antibody conjugated with Alexa Fluor 488 or 594. As shown in Figure 4.2B-D, treatment 
with RSPO1 or TGFβ increased co-localization of LGR5/RI, RII/LGR5 and RII/RI. 
These results indicate that LGR5 is a novel component of TGFβ receptor signaling 
complex and that RSPO-LGR5 activates TGFβ signaling through increasing this complex 
formation.  
We showed earlier that ectopic expression of LGR5 activated TGFβ promoter activity in 
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HCT116 cells in the absence of TGFβ RII (Figure 3.4A). To determine whether LGR5 
could form the complex with RI in the absence of RII, we treated HCT116 cells stably 
expressing LGR5 (HCT116/LGR5) with RSPO1. As a result, Smad2 phosphorylation 
was induced (Figure 4.2E). Protein lysates from the control or RSPO1-treated cells were 
immunoprecipitated with anti-LGR5 or anti-RI antibody followed by western blot 
analysis of expression of LGR5 and RI in the immunoprecipitated complexes. Co-IP 
results showed that RSPO1 increased the amount of RI associated with LGR5 (Figure 
4.2E). These results indicated that treatment with RSPO1 induced the complex formation 
between LGR5 and RI in the absence of RII.  
To demonstrate the clinical relevance of the activation of the TGFβ pathway by 
RSPO/LGR5, we determined the correlation of LGR5 expression with Smad2 
phosphorylation in the tissue samples of MSI patients. Since TGFβ RII is widely 
inactivated in MSI patients (Markowitz, Wang et al. 1995), the effect of TGFβ RII on 
TGFβ activation as reflected by Smad2 phosphorylation is minimized in these samples. 
IHC analysis showed a positive correlation between LGR5 and pSmad2 expression in 
MSI samples (Figure 4.2F).  These results indicated that LGR5-mediates the activation 
of TGFβ signaling in MSI patients. 
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Figure 4.2A-D RSPO-LGR5 Mediates TGFβ Signaling by Enhancing the Complex 
Formation with TGFβ  Receptors.  HCT116/RII/LGR5 cells were treated with 
500ng/ml RSPO1 (R) or 4ng/ml TGFβ (T) at 40% confluence for 15 minutes. A. IP and 
IB were performed as was describe in Figure 4.1. LRP6 were detected by anti-LRP6 
antibody. The activation of TGFβ signaling was determined by pSmad2. B. Confocal 
imaging of LGR5 (green) colocalization with TGFβRII (red) in control (a), under TGFβ 
treatment (b) and RSPO1 treatment (c). C. Confocal imaging of LGR5 (green) 
colocalization with TGFβRI (red) in control (d), under TGFβ treatment (e) and RSPO1 
treatment (f). D. Confocal imaging of TGFβRII (green) colocalization with TGFβRI (red) 
in control (g), under TGFβ treatment (h) and RSPO1 treatment (i) B-D lower panel. 
Quantifications of colocalizaion was determined by Person’s coefficient analysis. 












































































Figure 4.2E RSPO-LGR5 Mediates TGFβ Signaling Independent of TGFβ  RII. 
HCT116 cells were stably expressed with LGR5 and treated with RSPO1 under the 
condition described previously. E. Left panel: expression of LGR5, TGFβ RI and 
pSmad2 after RSPO1 treatment. Right upper panel:  IP of LGR5 followed by IB with 
TGFβ RI. Right lower panel: IP of TGFβ RI followed by IB with LGR5.  








Figure 4.2F. LGR5 Expression Positively Correlates with TGFβ  Activity in MSI 
Colon Cancer Patients. 19 MSI colon cancer patient samples were obtained from the 
UNMC tissue bank, followed by pSmad2 and LGR5 IHC staining. The upper panel 
showed representatives of the staining (× 20 magnification). The lower panel showed the 
correlation of LGR5 and pSmad2 staining in terms of intensity (Left) or percentage of 
positive cells (Right). The values are means of staining intensity or percentage of positive 
cells from multiple fields of each sample section. The correlation was established through 
Pearson's test (r = 0.7704 in intensity correlation, 0.8906 in percentage correlation; *** p 
< 0.001; n = 19). The equation was generated by lineage regression analysis. Dash lines 
indicate 95% confidence intervals of the slope.  
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MSI-LGR5 vs pSmad2 Intensity
Y = 0.7781*X + 9.632e+006
pearson r = 0.7704, *** P < 0.001 
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Discussion and Future Direction 
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TGFβ signaling functions as a tumor suppressor and is defective in most of late stage 
colon cancer cases (Cancer Genome Atlas 2012). We have shown in this study that 
RSPO-LGR5 activates TGFβ signaling and inhibits oncogenic phenotypes of colon 
cancer cells. More importantly, knockdown of LGR5 expression suppressed TGFβ 
signaling in vivo and increased colon cancer metastasis in an orthotopic model. RSPO-
LGR5-mediated activation of TGFβ signaling is dependent upon the RI kinase activity 
and expression of Smad2, Smad3 and Smad4. Mechanistically, LGR5 forms complexes 
with TGFβ RI and RII. Our studies have identified LGR5 as a novel signaling component 
of the TGFβ signaling pathway. 
LGR4, LGR5 and LGR6 are close relatives of the receptors for follicle stimulating 
hormone, luteinizing hormone and thyroid-stimulating hormone (Barker and Clevers 
2010). LGR6 marks multipotent stem cells in the epidermis (Snippert, Haegebarth et al. 
2010). Both LGR4 and LGR5 are co-expressed in the stem cells of intestine, colon, 
stomach and hair follicle (Barker, van Es et al. 2007, Jaks, Barker et al. 2008, Barker, 
Huch et al. 2010). We found that LGR5 is differentially expressed in colon cancer cell 
lines (Figure 3.1F) whereas LGR4 is ubiquitously expressed at similar levels and LGR6 
is absent from those cells (Figure S1).  Unlike other GPCRs, LGR4, LGR5 and LGR6 
are not coupled to either G proteins or β-arrestin when stimulated by RSPOs (Carmon, 
Gong et al. 2011). Instead, we show in this study that upon binding RSPOs, LGR5 forms 
a physical complex with TGFβ receptors RI and RII to amplify TGFβ signaling. 
Similarly, LGR4 and LGR6 also activate TGFβ signaling in colon cancer cells (Figure 
S2), indicating that it is a common function of this family. Since LGR4 is universally 
expressed and LGR5 suppression correlates with metastatic potential in colon cancer 
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cells, it is possible that LGR5 is a critical suppressor of colon cancer progression. 
RSPO-LGR5 has been shown to modulate Wnt canonical signaling in many different cell 
types including colon cancer cells (Geng, Chaudhuri et al. 2014, Tsuji, Kawasaki et al. 
2014, Wu, Qiu et al. 2014). Therefore, RSPO-LGR5-mediated Wnt activation seems to 
be cell context-dependent. In our studies, we found that RSPO-LGR5 can induce 
phosphorylation of LRP6 in most of the cancer cells, but none of them showed any 
significant change under Wnt reporter assay (data not shown), likely due to the 
ubiquitous and saturated Wnt activation in these cells. Nevertheless, RSPO-LGR5 
activates TGFβ signaling in all cell lines including those with mutated APC or β-catenin 
(i.e. HCT116 and FET, respectively) and in those with the wild type APC and β-catenin 
(i.e. RKO, Figure S3), suggesting that RSPO-LGR5 mediates TGFβ activation regardless 
of Wnt activation status. We show here that LGR5 forms complexes with TGFβ 
receptors. It is yet to be investigated what the determining factors are for LGR5 to bind 
either or both of the Wnt or TGFβ receptors. 
LGR5 activates TGFβ signaling in HCT116 cells that do not express TGFβ RII (Figure 
3.4A) and treatment with RSPO increases TGFβ pathway activation in these cells 
(Figure 3.4B). These results suggest that RSPO-LGR5 could activate TGFβ signaling 
independent of RII. Knockdown of LGR5 in FET cells that express both RII and LGR5 
reduces basal level of TGFβ activity and fold of TGFβ activation induced by RSPO 
(Figure 3.4C), suggesting that TGFβ-RII mediated TGFβ activation is independent of 
LGR5. In addition, treatment of FET and CBS cells with both TGFβ and RSPO induces 
much higher TGFβ activation than either treatment alone (Figure 3.4D). RI kinase 
inhibitor almost completely blocked TGFβ activation in all the treatments (Figure 3.4D), 
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indicating RSPO-LGR5 functions through TGFβRI. Furthermore, either TGFβ or RSPO 
induces complex formation of RI/RII/LGR5 and phosphorylation of Smad2 (Figure 4.2). 
Based on these results, we propose an updated model of TGFβ signaling (Figure 5): 
TGFβ and RSPO bind TGFβ RII and LGR5 respectively. Activated RII or LGR5 then 
form complexes with TGFβ RI and activate RI, which leads to phosphorylation and 
activation of Smads downstream. In the presence of RII, TGFβ-RII activates TGFβ 
signaling through RII binding with RI. Likewise, in the presence of LGR5, RSPO-LGR5 
mediates TGFβ signaling through LGR5 association with RI. When both RII and LGR5 
are present, RII and LGR5 both associates with RI and TGFβ signaling is further 
amplified. Therefore, TGFβ-RII and RSPO-LGR5 transduce TGFβ signaling 
independently as well as collaborately through the downstream RI-Smad pathway. 
Our studies have significant implications for colon cancer development. According to our 
data, there are at least two ways to activate TGFβ signaling, TGFβ binding to RII and 
RSPO binding to LGR5. When both are present, TGFβ effect is greatly enhanced. 
Absence of either one will decrease TGFβ effect, but not be able to completely evade this 
tumor suppressor mechanism in colon cancer. Therefore, loss or reduction of both RII 
and LGR5 expression would significantly enhance the capacity of cancer cells to escape 
TGFβ tumor suppressor function, leading to cancer progression, poor prognosis and/or 
survival of colon cancer patients. Although loss of RII or decrease of LGR5 expression 
has been reported in colon cancer studies, decreased expression of both simultaneously 
has not been examined. Further studies of RII and LGR5 expression in human patient 
samples would be needed to investigate whether they could be used as potential 
biomarkers in colon cancer. Our results will also guide future studies towards the 
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application of RSPOs in treating colon cancers with elevated LGR5 expression. In 
addition, this study establishes a novel connection between an adult intestinal stem cell 






Figure 5. TGFβ  Signaling Pathway Activation Models. Without the presence of RII, 
RSPO-LGR5 can directly activate RI to facilitate downstream Smads activation (B). With 
the presence of RII, RI activation can go through the canonical TGFβ-RII pathway (A) or 













Figure S2. LGR4 and LGR6 Activate TGFβ  Signaling Pathway in HCT116 Cells. 
TGFβ reporter assay in HCT116 cells transfected with different dose of LGR4 and LGR6 
expression plasmid (0, 25, 50 and 75ng). The data are presented as the mean ± SEM. 
Statistical significance was determined by Student’s t-test.  ** P <0.01, *** P < 0.001 
comparing to 0 ng group. 



































Figure S3. LGR5 Activates TGFβ  Signaling Pathway in RKO Cells. TGFβ reporter 
assay in RKO cells transfected with different dose of LGR5 expression plasmid (0, 25, 50 
and 75ng). The data are presented as the mean ± SEM. Statistical significance was 
determined by Student’s t-test. *** P < 0.001 comparing to 0 ng group. 
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